<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03886103</url>
  </required_header>
  <id_info>
    <org_study_id>PXL770-005</org_study_id>
    <nct_id>NCT03886103</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Metabolism of (14C)-Labelled PXL770</brief_title>
  <official_title>Pharmacokinetics and Metabolism of [14C]-Labelled PXL770 Following a Single Oral Administration in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-dose, single center, single-period, open-label, non-randomized, mass balance
      recovery study in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 6, 2019</start_date>
  <completion_date type="Actual">March 15, 2019</completion_date>
  <primary_completion_date type="Actual">March 15, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass balance recovery</measure>
    <time_frame>From day 1 to day 7</time_frame>
    <description>Mass balance recovery of total radioactivity in all excreta: cumulative recovery (CumAe) and cumulative recovery expressed as a percentage of the dose (Cum%Ae)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK profile of total radioactivity</measure>
    <time_frame>From day 1 to day 7</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK profile of PXL770</measure>
    <time_frame>From day 1 to day 7</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>From day 1 to day 7</time_frame>
    <description>Incidence of Treatment-Emergent Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Healthy volunteer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single of 14C-PXL770</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>14C labeled PXL770</intervention_name>
    <description>Single administration</description>
    <arm_group_label>Healthy volunteer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Caucasian males

          -  Age 30 to 65 years

          -  BMI 18.5 to 32.0 kg/m2 and body weight of 55 to 95 kg.

          -  Must be willing and able to communicate and participate in the whole study

          -  Must have regular bowel movements (ie, average stool production of ≥1 and ≤3 stools
             per day)

          -  Must provide written informed consent

          -  Regular alcohol consumption of 4-14 units of alcohol per week (1 unit = ½ pint beer,
             or a 25 mL shot of 40% spirit, 1.5 to 2 Units = 125 mL glass of wine, depending on
             type)

          -  Must agree to adhere to the contraception

        Exclusion Criteria:

          -  Subjects who have received any IMP in a clinical research study within the previous 3
             months or 90 days prior to Day 1

          -  any drug or alcohol abuse

          -  Current smokers and those who have smoked within the last 12 months.

          -  Radiation exposure, including that from the present study, excluding background
             adiation but including diagnostic x-rays and other medical exposures, exceeding 5 mSv
             in the last 12 months or 10 mSv in the last 5 years.

          -  No occupationally exposedworker, as defined in the Ionizing Radiation Regulations
             2017, shall participate in the study

          -  Clinically significant abnormal biochemistry, hematology, coagulation or urinalysis as
             judged by the investigator

          -  Positive test for HIV, HBV, HBC

          -  eGFR &lt;80 mL/min

          -  History of clinically significant cardiovascular, renal, hepatic, chronic respiratory
             or GI disease, neurological or psychiatric disorder, as judged by the investigator

          -  Known sensitivity to any of the constituents or excipients of the study drug or
             history of relevant drug and/or food allergy (anaphylactic, anaphylactoid reactions)

          -  History of drug-induced Torsade de Pointe or presence of a familial long QT syndrome

          -  Mental handicap
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Quotient</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

